Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The purpose of this study is to compare the safety and efficacy of epirubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide in lymph node negative, estrogen receptor (ER) positive, human epithelial growth factor receptor 2 (HER2) negative breast cancer patients as adjuvant chemotherapy.
Epistemonikos ID: 0e8fcb805efad3909f4de62a370b6d3e76e4b87b
First added on: May 12, 2024